Compare · ORKA vs QCLS
ORKA vs QCLS
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Q/C Technologies Inc. (QCLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QCLS operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $7.15B, about 2777.3x QCLS ($2.6M).
- ORKA has been more active in the news (9 items in the past 4 weeks vs 1 for QCLS).
- ORKA has more recent analyst coverage (11 ratings vs 0 for QCLS).
- Company
- Oruka Therapeutics Inc.
- Q/C Technologies Inc.
- Price
- -
- -
- Market cap
- $7.15B
- $2.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 9
- 1
- Recent ratings
- 11
- 0
Latest ORKA
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,049,658 worth of shares (10,000 units at $104.97) as part of a pre-agreed trading plan (SEC Form 4)
- Director Ball Kristine M exercised 18,000 shares at a strike of $6.84 and sold $1,888,749 worth of shares (18,000 units at $104.93) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
- General Counsel Quinlan Paul T sold $706,735 worth of shares (9,000 units at $78.53) as part of a pre-agreed trading plan (SEC Form 4)
Latest QCLS
- Q/C Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Executive Chairman Silverman Joshua was granted 94,010 shares, increasing direct ownership by 80% to 210,845 units (SEC Form 4)
- Amendment: Executive Chairman Silverman Joshua was granted 16,806 shares, increasing direct ownership by 17% to 116,835 units (SEC Form 4)
- Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab
- SEC Form 3 filed by new insider Ehrlichman Yossef
- Q/C Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development
- Q/C Technologies Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Fagan Charles Todd
- SEC Form 10-Q filed by Q/C Technologies Inc.